Association between lung function and exacerbation frequency in patients with COPD

Por Hoogendoorn, Martine, Feenstra, Talitha L, Hoogenveen, Rudolf T, Al, Maiwenn, Mölken, Maureen Rutten-van
Publicado em 2010

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.

Por Whiting, Penny, Al, Maiwenn, Burgers, Laura, Westwood, Marie, Ryder, Steve, Hoogendoorn, Martine, Armstrong, Nigel, Allen, Alex, Severens, Hans, Kleijnen, Jos
Publicado no Health Technol Assess (2014)

Projecting the COPD population and costs in England and Scotland: 2011 to 2030

Por McLean, Susannah, Hoogendoorn, Martine, Hoogenveen, Rudolf T., Feenstra, Talitha L., Wild, Sarah, Simpson, Colin R., Mölken, Maureen Rutten-van, Sheikh, Aziz
Publicado no Sci Rep (2016)

Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial

Por van Wetering, Carel R, van Nooten, Floortje E, Mol, Stijn J M, Hoogendoorn, Martine, Rutten-van Mölken, Maureen P M H, Schols, Annemie M
Publicado em 2008

Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources

Por Hoogendoorn, Martine, Feenstra, Talitha L, Boland, Melinde, Briggs, Andrew H, Borg, Sixten, Jansson, Sven-Arne, Risebrough, Nancy A, Slejko, Julia F, Rutten-van Mölken, Maureen PMH
Publicado no Int J Chron Obstruct Pulmon Dis (2017)